Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Progressive Dementia with Other Neurological Abnormalities
Upcoming SlideShare
Loading in...5
×
 

Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Progressive Dementia with Other Neurological Abnormalities

on

  • 216 views

 

Statistics

Views

Total Views
216
Views on SlideShare
216
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Progressive Dementia with Other Neurological Abnormalities Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Progressive Dementia with Other Neurological Abnormalities Document Transcript

  • Global Markets for Treatments of Dementia and MovementDisorders -- Focus on Progressive Dementia with OtherNeurological AbnormalitiesReport Details:Published:September 2012No. of Pages: 160Price: Single User License – US$3900REPORT HIGHLIGHTS•The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.•The global sales of drugs to treat progressive dementia with other neurological abnormalities expected to reach $537.2 million in 2012 and $913.7 million by 2017, at a CAGR of 11.2% over the five-year forecast period.•Sales of drugs to treat Huntington’s disease patients with progressive dementia and other neurological abnormalities expected to reach $354.4 million in 2012 and further increase to $566.8 million in 2017, at a CAGR of 9.8% over the five-year forecast period.INTRODUCTIONSTUDY OBJECTIVESBCC’s goal in conducting this study is to provide an overview of the current and futurecharacteristics of the global markets for treatments for syndromes of dementia and movementdisorders. The key objective is to present a comprehensive analysis and the future direction of themarket as it shapes drug and therapy development.This report explores present and future strategies within the neurodegenerative disorder market,which includes treatments and therapies for progressive dementia, progressive dementia withother neurological abnormalities and movement disorders. Market gains, setbacks and needs arediscussed in this report. Comparisons, usage and the advantages and disadvantages of differenttypes of technologies, including small molecules and monoclonal antibodies, are also presented inthis report.A detailed analysis of the structure of the syndromes of dementia and movement disorder industryhas been conducted. Revenues are broken down by neurodegenerative disease and primaryclinical/pathological feature. Sales figures are estimated for the five-year period from 2012through 2017.
  • Applications for syndromes of dementia and movement disorder treatments, or therapeutictechnologies, are also discussed separately in the report, with an emphasis on small molecule andmonoclonal antibodies technology. The report also covers significant patents and their allotmentin each category.REASONS FOR DOING THIS STUDYExtensive research in the field of syndromes of dementia and movement disorders and companycollaborations with research institutes have highlighted the importance of understanding the natureof these disorders. New technological developments are providing disease-modifying therapiesfor the late stages of the disorders. Collaborations between research institutes and pharmaceuticalcompanies are on the rise as state-of-the-art technology is being explored to develop moreefficient products and therapies.R&D spending, along with increasing competition, patent expiries and new technologies are takingthe market in a new direction. Global market revenues increased from 2009 to 2011 and areexpected to continue to show growth over the forecast period as new advances, launches andcollaborations continue to influence the market. This study looks at most of the systems affectedby these factors.Acquisition strategies and collaborations by companies are also covered in this report. This studyalso discusses the strength and weaknesses of each type of technology in light of the newtechnologies, growing competition and changing customer needs.CONTRIBUTIONS OF THE STUDY AND FOR WHOMThis study contributes to the areas of market growth in treatments for Alzheimer’s disease, Lewybody dementia, Pick’s disease, Huntington’s disease, corticobasal ganglionic degeneration,Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy and Hallervorden-Spatz disease. Pharmaceutical biotechnical companies, research institutes and physicians willfind this study to be of interest.SCOPE OF THE STUDYThe scope of this study encompasses the neurodegenerative disorders in the pharmaceutical andbiotechnology markets. BCC analyzes each market and its applications, regulatory environment,technology involved, market projections and market share. Technological issues include the latesttrends and developments. The emerging market for enzyme inhibitors includes countries such asIndia, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and Mexico.METHODOLOGYBCC conducted a comprehensive literature search, which included technical newsletters andjournals, and many other sources. Data were collected through interviews and correspondencewith manufacturers of enzyme inhibitors’ technical experts. Projections were based on estimatessuch as the current number of end users, potential end users, mergers and acquisitions, andmarket trends.INFORMATION SOURCESMany companies within the industry were surveyed to obtain data for this study. Included weremanufacturers and end users of enzyme inhibitors in therapeutic categories and various diseasesectors industries. Data were gathered from various industry sources. BCC spoke with officialswithin the industry, consulted newsletters, company literature, product literature and a host of
  • technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by keyterminology were completed. In addition, data were compiled from current financial, trade andgovernment sources.Get your copy of this report @http://www.reportsnreports.com/reports/194887-global-markets-for-treatments-of-dementia-and-movement-disorders-focus-on-progressive-dementia-with-other-neurological-abnormalities.htmlMajor points covered in Table of Contents of this report includeTable of ContentsChapter- 1: INTRODUCTIONSTUDY OBJECTIVESREASONS FOR DOING THIS STUDYCONTRIBUTIONS OF THE STUDY AND FOR WHOMSCOPE OF THE STUDYMETHODOLOGYINFORMATION SOURCESABOUT THE AUTHORRELATED BCC RESEARCH REPORTSBCC ONLINE SERVICESDISCLAIMERChapter- 2: EXECUTIVE SUMMARYTable Summary : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, THROUGH 2017Figure Summary : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, 2010-2017Chapter- 3: OVERVIEWTHE BRAINCLASSIFICATION OF NEURODEGENERATIVE DISORDERSNEURODEGENERATIVE DISORDERSDIAGNOSTIC TESTS FOR NEURODEGENERATIVE DISORDERSChapter- 4: REGULATORY ASPECTSINTRODUCTIONDRUG APPROVALSREGULATORY DEVELOPMENTS AFFECTING SYNDROMES OF DEMENTIA ANDMOVEMENT DISORDER PRODUCTSChapter- 5: NEW DEVELOPMENTSTable 6 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, 2012Table 7 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, 2011Table 8 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
  • AND MOVEMENT DISORDERS, 2010Chapter- 6: GLOBAL MARKETSMARKETS BY CLINICAL/PATHOLOGICAL FEATUREMARKET BY DISEASE TYPEMARKET BY REGIONMARKETS BY TECHNOLOGYChapter- 7: MARKET FOR DRUGS TO TREAT PROGRESSIVE DEMENTIA WITH OTHERNEUROLOGICAL ABNORMALITIESMARKET BY DISEASE TYPEMARKET BY REGIONREGIONAL MARKETS BY DISEASE TYPEMARKET BY TECHNOLOGYINDUSTRY STRUCTUREChapter- 8: PATENT ANALYSISPATENTS ISSUED BY YEARPATENTS BY DISEASE CATEGORYPATENTS BY DISEASE TYPEPATENTS BY COUNTRYPATENTS BY COMPANYChapter- 9: CURRENT SITUATIONMARKET TRENDSOVERALL DRIVERS OF THE MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERSOTHER FACTORS AFFECTING THE MARKETCOLLABORATIONS/MERGERS AND ACQUISITIONSChapter- 10: COMPANY PROFILESABBOTT LABORATORIESABLYNX NVACCERA INC.ACORDA THERAPEUTICS INC.ACTAVIS ELIZABETHAFFIRIS AGALLIANCE PHARMA PLCALLON THERAPEUTICS INC.ALPHAPHARMALZHYME LTD.AMERICAN REGENT INC.APOTEX INC.APOTHECA INC.ASTELLAS PHARMA INC.ASTRAZENECA GMBHAUROBINDO PHARMA LTD.
  • BAXTER INTERNATIONAL INC.BELLUS HEALTH INC.BOEHRINGER INGELHEIM LTD.BRISTOL-MYERS SQUIBBBRYANT RANCH PREPACKCADILA HEALTHCARE LTD.CARACO PHARMACEUTICAL LABORATORIESCARDINAL HEALTHCELLZOME AGCIPLA LTD.COGNITION THERAPEUTICS INC.COLUCID PHARMACEUTICALS INC.COMENTIS INC.CORTEX PHARMACEUTICALSCYTOS BIOTECHNOLOGY AGDAIICHI SANKYO CO. LTD.DR. REDDYS LABORATORIES LTD.EISAI CO. LTD.ELAN PHARMA INTERNATIONAL LTD.ELI LILLY AND CO.ENDO PHARMACEUTICALS INC.ENVIVO PHARMACEUTICALSEVOTEC AGEPITOMICS INC.EXONHIT THERAPEUTICS SAFOREST LABORATORIES INC.GLAXOSMITHKLINE PLCGLENMARK GENERICS LTD.H. LUNDBECK A/SHAMELN PHARMACEUTICALS LTD.HELICON THERAPEUTICS INC.HOSPIRA INC.INTELLECT NEUROSCIENCES INC.INTRA-CELLULAR THERAPIES INC.JAZZ PHARMACEUTICALS PLCMAJOR PHARMACEUTICALSMEDIVATION INC.MEMORY PHARMACEUTICALS CORP.MERCK SERONOMERCK SHARP & DOHME LTD.MERZ PHARMA GMBH & CO KGAAMITHRIDION INC.
  • MYLAN PHARMACEUTICALSNEUREN PHARMACEUTICALS LTD.NEURO-HITECH INC.NEUROPTIX CORP.NEUROSEARCH A/SNEWRON PHARMACEUTICALS SPANOSCIRA SANOVARTIS AGNYMOX PHARMACEUTICAL CORP.ORCHID CHEMICALS & PHARMACEUTICALS LTD.ORION CORP.ORTHO-MCNEIL JANSSEN PHARMACEUTICALS INC.PAR PHARMACEUTICALSPERRIGO CO.PFIZER INC.PHARNEXTPHYSICIANS TOTAL CARE INC.PLIVA HRVATSKA D.O.O.PRASCO LABORATORIESRANBAXY LABORATORIES LTD.ROCHE HOLDING LTD.ROXANE LABORATORIES INC.SANDOZ INTERNATIONAL GMBHSANOFISANTHERA PHARMACEUTICALSSHIONOGI & CO.STADA ARZNEIMITTEL AGSUN PHARMATAJ PHARMACEUTICALS LTD.TAKEDA PHARMACEUTICAL CO. LTD.TERCICA INC.TEVA PHARMACEUTICAL INDUSTRIES LTD.TORRENT PHARMAUCB SAUDL LABORATORIESUPSHER-SMITH LABORATORIESVALEANT PHARMACEUTICALSVERNALIS PLCWATSON PHARMACEUTICALS INC.WEST-WARD PHARMACEUTICALChapter- 11: APPENDIX I: ABBREVIATIONS
  • List of TablesSummary Table : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, THROUGH 2017Table 1 : CLASSIFICATION OF SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERSBY PRIMARY CLINICAL/PATHOLOGICAL FEATURETable 2 : ANDA AND NDA APPROVALS OF DRUGS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012Table 3 : PENDING NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT SYNDROMESOF DEMENTIA AND MOVEMENT DISORDERSTable 4 : FDA DRUG SAFETY ALERTS, 2010 TO MARCH 2012Table 5 : FDA RECALLS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA ANDMOVEMENT DISORDERS, 2010 TO MARCH 2012Table 6 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, 2012Table 7 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, 2011Table 8 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, 2010Table 9 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017Table 10 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREATNEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011Table 11 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJORNEURODEGENERATIVE DISORDERS, THROUGH 2017Table 12 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMESOF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE TYPE, 2011Table 13 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS BY REGION, THROUGH 2017Table 14 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMESOF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011Table 15 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, THROUGH 2017Table 16 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMESOF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011Table 17 : CHDI FOUNDATIONS’ KEY DEVELOPMENTS IN TREATING HUNTINGTON’SDISEASETable 18 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVEDEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE,THROUGH 2017Table 19 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREATPROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASETYPE, 2011
  • Table 20 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVEDEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, THROUGH 2017Table 21 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREATPROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION,2011Table 22 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HUNTINGTON’SDISEASE BY REGION, THROUGH 2017Table 23 : GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONICDEGENERATION BY REGION, THROUGH 2017Table 24 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVEDEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, THROUGH2017Table 25 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREATPROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BYTECHNOLOGY, 2011Table 26 : LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TOTREAT HUNTINGTON’S DISEASETable 27 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USEDTO TREAT HUNTINGTON’S DISEASE, 2011Table 28 : LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TOTREAT HUNTINGTON’S DISEASETable 29 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USEDTO TREAT CORTICOBASAL GANGLIONIC DEGENERATION, 2011Table 30 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA ANDMOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012Table 31 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA ANDMOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012Table 32 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA(PROGRESSIVE DEMENTIA) BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012Table 33 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY DISEASE TYPE, 2010-MARCH 2012Table 34 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA(PROGRESSIVE DEMENTIA) BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012Table 35 : U.S. PATENT SHARES OF DRUGS USED TO TREAT PROGRESSIVE DEMENTIABY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012Table 36 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012Table 37 : U.S. PATENT SHARES OF DRUGS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012Table 38 : NUMBER OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OFDEMENTIA (PROGRESSIVE DEMENTIA) BY COMPANY, 2010-MARCH 2012Table 39 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER
  • SYNDROMES BY COMPANY, 2010-MARCH 2012List of FiguresSummary Figure : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIAAND MOVEMENT DISORDERS, 2010-2017Figure 1 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS, 2010-2017Figure 2 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREATNEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011Figure 3 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJORNEURODEGENERATIVE DISORDERS, 2010-2017Figure 4 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMESOF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE, 2011Figure 5 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS BY REGION, 2010-2017Figure 6 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMESOF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011Figure 7 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2010-2017Figure 8 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMESOF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011Figure 9 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVEDEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, 2010-2017Figure 10 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREATPROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASETYPE, 2011Figure 11 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVEDEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2010-2017Figure 12 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREATPROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION,2011Figure 13 : GLOBAL SALES OF DRUGS USED TO TREAT HUNTINGTON’S DISEASE BYREGION, 2010-2017Figure 14 : GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONICDEGENERATION BY REGION, THROUGH 2017Figure 15 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVEDEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2010-2017Figure 16 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREATPROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BYTECHNOLOGY, 2011Figure 17 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS FORUSED TO TREAT HUNTINGTON’S DISEASE, 2011
  • Figure 18 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUGS USED TO TREATCORTICOBASAL GANGLIONIC DEGENERATION, 2011Figure 19 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA ANDMOVEMENT DISORDERS ISSUED PER YEAR, 2010—MARCH 2012Figure 20 : PERCENTAGE OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OFDEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012Figure 21 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA ANDMOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012Figure 22 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA BYCLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012*Figure 23 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY DISEASE TYPE, 2010-MARCH 2012Figure 24 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA(PROGRESSIVE DEMENTIA) BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012Figure 25 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDERSYNDROMES BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012Contact: sales@reportsandreports.com for more information.